<DOC>
	<DOCNO>NCT01927133</DOCNO>
	<brief_summary>`` Mortality related complication cirrhosis , ( hemorrhage , hepatic insufficiency primary liver cancer ) 15,000 per year France . These mortality increase , despite advanced fibrosis identify non-invasive biomarkers treat , 10 year onset complication cancer . The main goal FIBROFRANCE project start 1997 ( initially call MULTIVIRC group ) demonstrate performance serum biomarkers frequent chronic liver disease , estimate dynamic fibrosis progression finally demonstrate feasibility fibrosis screen French people . The different cohort FIBROFRANCE ( HCV , HBV , ALD , NAFLD ) permit many publication among 186 publication group since 1986 field liver fibrosis . These publication include discovery validation non-invasive biomarkers ( Poynard Gastroenterology 1997 , Imbert-Bismut Lancet 2001 , Poynard BMC Gastro 2007 ) , model fibrosis progression regression ( Poynard Lancet 1997 , Poynard Gastroenterology 2002 , Poynard J Hepatol 2003 ) fibrosis screening ( Ratziu APT 2007 , Jacqueminet Clin Gastrenterol Hepatol 2008 ) . This research conduct Pitié-Salpêtrière hospital biochemical clinical part connection national international network . Several panel identify predictive FibroTest patent ( US Patent Office 6.631.330 ) launch 2002 . This first fibrosis biomarker available worldwide ( 50 country include USA FibroSURE ) 1 million prescription 2002-2013 . FibroTest , validate first hepatitis C hepatitis B alcoholic liver disease metabolic syndrome . Therefore possible screen advance fibrosis 4 frequent liver disease : alcohol , hepatitis C B , metabolic syndrome ( diabetes , overweight , hyperlipemia ) . For patient detect therapeutic option cure fibrosis reduce progression cirrhosis cancer . FibroTest recommend alternative biopsy several guideline ( AFEF , APASL , EASL CASLD ) recently US overview ( Chou Annals 2013 ) . It reimburse France chronic hepatitis C. Several factor fibrosis progression present subject , i.e . overweight excessive alcohol consumption . Therefore realistic screenng strategy conduct without take account Interdependence different risk factor . Three biomarkers fibrosis-associated liver injury develop validated FIBROFRANCE cohort : SteatoTest steatosis ( Poynard Comp Hepatol 2005 ) , NashTest non-alcoholic steatohepatitis ( Poynard EASL 2006 ) , AshTest alcoholic steatohepatitis ( Naveau J Hepatol 2006 ) . For purpose different cohort already use diagnostic validation follow long term prognostic validation : FIBROFRANCE-ALD ( Naveau Hepatology 2010 ) , FIBROFRANCE-NAFLD include dyslipidemia cohort ( Ratziu APT 2007 ) diabetes cohort ( Jacqueminet Clin Gastrenterol Hepatol 2008 ) . These cohort allow assess prevalence fibrosis specific risk fibrosis progression imputable steatosis steatohepatitis .</brief_summary>
	<brief_title>LIVER FIBROSIS PREVALENCE IN FRANCE</brief_title>
	<detailed_description>`` This initial version FIBROFRANCE project strated 1997 . Methods The strategy choose screen advanced fibrosis several group patient different level risk order reconstruct French prevalence thereafter . A national screening suggest accord identify risk factor . Rational prior hypothesis The simple rational concept screen patient complication cirrhosis . ( Figure 1 ) . Figure 1 : Fibrosis progression five consecutive stage : F0 fibrosis , F1 mild fibrosis without septum , F2 moderate fibrosis septum , F3 severe fibrosis many septum , F4 cirrhosis . Advanced fibrosis define presence stage F2-F3-F4 . The aim study demonstrate screen possible stage F2 many year complication . From previous modeling ( Figure 2 ) suggest efficient screening must start around age 40 year majority high-risk group around 30 year old HIV coinfected patient . Population include Five major group 15 cohort different population risk include . Five group high risk include : patient hepatitis C , B , heavy alcohol drinker patient metabolic risk factor diabetic hyperlipemics . These population choose blood sample easily available . The high number permit reconstruct French prevalence take account major characteristic subject include ( age , gender , socio economic status ) know prevalence risk factor ( HBV HCV prevalence , diabetes , hyperlipemia heavy drinker 's prevalence ) . Characteristics subject record item The following characteristic record study : age , gender , high-risk factor , fibrosis stage activity grade . In FibroFrance ANR cohorts follow factor record used sensitivity analysis prevalence estimate : socio-economic status , body mass index , area residence , alcohol consumption , metabolic syndrome factor , cholesterol , triglyceride , glucose . All data record anonymously code number declare CNIL . Endpoints The main endpoint French prevalence advance fibrosis cirrhosis . The estimate calculate accord age gender adjust absence presence high risk factor French population . Non-high risk group represent France 48,000,000 people high risk group 12,000,000 people . The non-high risk group derive estimate blood donor , free screening center , social security center exclusion subject high-risk factor assess three cohort : heavy drinker , HBV , HIV , diabetes , hyperlipemia . The final target national screen take account relative risk attribute predicted steatosis steato-hepatitis . Estimates steatosis steatohepatitis secondary endpoint . Biomarkers FibroTest-ActiTest , SteatoTest , NashTest , AshTest perform reference laboratory ( GHPS ) use recommend pre analytical analytical procedure . Results provide estimate stage grade result profile risk false positive negative . All patient advance fibrosis identify FibroTest contact Liver reference center organize management . Elastometry ( FibroScan ) ultrasonography perform advanced fibrosis endoscopy cirrhosis predict . Statistical analysis Prevalence express mean 95 % confidence interval . Sensitivity analyse performed assess impact follow factor prevalence estimate : socio economic status , body mass index , area residence , non-heavy drinker ( &lt; 50g/day ) , metabolic syndrome factor ( ATP III definition ) univariate multivariate analysis use multiple regression analysis , together age gender . The feasibility project check patient chronic hepatitis C , B well patient alcoholic non alcoholic liver steatosis ( see Fibrochure annex detail reference ) . The risk false positive false negative FibroTest ( FT ) , also check large population hepatitis C blood donor . These study allow u expand screen community base population . Blood donor ( BD ) Security algorithm ( SA ) use time calculate FT alert user correct potential error data entry 6 FT component different cohort . One SA1 detect abnormal value ( AV ) outside 98 % percentile . Another SA2 detects , HR profile false positive ( HR-FP ) false negative ( HR-FN ) serum , define serum switch one component median value particular component , associate dramatic change FT , great +0.30 . A total 954 Blood Donors ( HBV , HCV , HIV neg ) prospectively include ; BMI , daily alcohol consumption treatment assess . FT perform fresh serum accord analytical recommendation . Mean age pts 50 yr , 45 % female . SA2 detect 3,965 test ( 5.05 % ) HR profile . The frequent AV observe haptoglobin &lt; 0.12 g/L 3,562 pt ( 4.53 % ) , among 614 HR-FP case ( 0.78 % ) suspect hemolysis , component concordant favor significant fibrosis . HR-FP due possible Gilbert Syndrome observe 921 ( 1.17 % ) . Mean age BD 36 yr , 49 % female , BMI 23.4 Kg/M2 ; 265 ( 28 % ) receive treatment : 125 ( 13 % ) oestro-progestative ( OP ) , 20 ( 2 % ) hypolipemiant , 16 ( 2 % ) anti-histaminic , 11 ( 1 % ) thyroid hormone , 11 benzodiazepine ( 1 % ) ; 203 ( 21 % ) BD totally abstinent , 650 ( 68 % ) drunk less 10g , 101 10-50g/day none drunk . SA2 detect 29 ( 3 % ) HR profile include 9 Gilbert ( 0.9 % ) , 4 HR-FP hemolysis profile ( 0.4 % ) . Among 925 interpretable BD , median FT 0.08 ( range 0.01-0.46 ) , AT 0.06 ( 0.01-0.66 ) . No subject severe fibrosis F3F4 F2 , 909 ( 98.3 % ) none minimal fibrosis ( FT &lt; 0.32 ) . FT-AT associated age , weight , BMI treatments OP : FT , low 125 woman treat OP ( median 0.0490 ; 95 % CI 0.044-0.058 ) non treat ( 0.0659 ; 0.064-0.072 ; P=0.01 ) . Mean age BD 36 yr , 49 % female , BMI 23.4 Kg/M2 ; 265 ( 28 % ) receive treatment : 125 ( 13 % ) oestro-progestative ( OP ) , 20 ( 2 % ) hypolipemiant , 16 ( 2 % ) anti-histaminic , 11 ( 1 % ) thyroid hormone , 11 benzodiazepine ( 1 % ) ; 203 ( 21 % ) BD totally abstinent , 650 ( 68 % ) drunk less 10g , 101 10-50g/day none drunk . SA2 detect 29 ( 3 % ) HR profile include 9 Gilbert ( 0.9 % ) , 4 HR-FP hemolysis profile ( 0.4 % ) . Among 925 interpretable BD , median FT 0.08 ( range 0.01-0.46 ) , AT 0.06 ( 0.01-0.66 ) . No subject severe fibrosis F3F4 F2 , 909 ( 98.3 % ) none minimal fibrosis ( FT &lt; 0.32 ) . FT-AT associated age , weight , BMI treatments OP : FT , low 125 woman treat OP ( median 0.0490 ; 95 % CI 0.044-0.058 ) non treat ( 0.0659 ; 0.064-0.072 ; P=0.01 ) . Diabetics ( DI ) Mortality relate cirrhosis increase patient insulino-resistance factor . Type 2 diabetic patient ( DI ) vs non-DI high risk non-alcoholic fatty liver disease ( NAFLD ) liver cancer death . 411 Consecutive DI see diabetes unit , ( HCV HBV neg ) , prospectively include , well prospective control group blood donor ( BD ) . FT perform blindly clinical biological data , accord analytic recommendation security algorithms permit exclude high-risk ( HR ) profile false negative ( FN ) positive FT ( FP ) . Analysis use univariate comparison BD match gender , age , alcohol consumption BMI , multivariate logistic regression . Among DI 53 % male , mean age 55yrs , 66 % DI type 2 ; 80 % fast glucose ≥6.1mmol/L , 67 % ( 257/382 ) glycohemoglobin ( glyHb ) ≥7.5 % , 43 % ( 164/382 ) cholesterol ≥2.0 g/L , 29 % ( 111/382 ) triglyceride ≥1.5g/L , 50 % BMI ≥27 , 48 % arterial hypertension , 72 % alcohol consumption , 26 % consumption ≤50g/d , 2 % &gt; 50 g/d . BD young ( 36yr ) , low BMI alcohol consumption similar . F2F3F4 identify FT 41/411 ( 10 % ) DI , include 16 F2 , 12 F3 13 F4 , v none F2F3F4 among 925 BD ( P &lt; 0.0001 ) . Among DI type 2 , 11 % F2F3F4 vs 2 % type 1 ( p=0.01 ) . DI independent significant factor associate F2F3F4 multivariate regression analysis ( P &lt; 0.0001 ) . After exclusion 93 DI match high age BD , still 8.8 % ( 28/318 ) F2F3F4 DI versus 0 % BD ( P &lt; 0.0001 ) . Among 41 DI F2F3F4 , 22 ALT &lt; 50IU/L , 10 GGT &lt; 50 IU/L , 10 normal , 19 elevate 31 one . Only 2 DI overt clinical-biological sign cirrhosis . Conclusion : The prevalence advance fibrosis , estimate FibroTest , high ( 10 % ) diabetic patient follow tertiary center . This study strongly suggest non-invasive biomarkers could useful screen advanced fibrosis type 2 diabetic patient prevent liver mortality . Patients hyperlipemia ( HL ) A consecutive cohort HL , ( HCV , HBVneg ) , prospectively follow lipid center serum ( stored -80 ) retrospectively analyze ; control group blood donor ( BD ) prospectively include . FT perform blindly clinical biological data , accord analytic recommendation include security algorithm permit exclude extreme value high-risk profile false negative positive ( HR ) . A total 2,834 HL include ( 51 % female , median age 49 year ) ; 83 % cholesterol &gt; 200mg/dl , 94 % LDL-C &gt; 100mg/dl , 21 % HDL-C &gt; 70mg/dl , 16 % triglyceride &gt; 200mg/dl . 36 % BMI &gt; 27 , 32 % insulin &gt; 10mIU/ml , 39 % arterial hypertension , 15 % HOMA &gt; 3.8 13.2 % fast glucose &gt; 6mmol . GGT ALT &gt; 50 IU/L 458 HL ( 24 % ) . F2F3F4 identify FT 53/1909 ( 2.8 % ) HL , include 31 F2 , 14 F3 , 3 F3-F4 4 F4 versus ( 0 % ) among 925 BD ( P &lt; 0.0001 ) . Among 53 F2F3F4 42 ALT &lt; 50IU/L , 27 GGT &lt; 50 IU/L , 24 normal , 8 elevate 29 least one . Factors significantly ( p &lt; 0.01 ) associate fibrosis univariate analysis high age , BMI , triglyceride , uricemia , insulinemia , low HDL cholesterol . Drugs alcohol consumption associate fibrosis . In multivariate logistic regression insulin [ Odds ratio 43.7 , CI ( 1.5 ; 61.0 ) ; P=0.001 ] significant risk factor . In patient insulinemia &gt; 10mIU/ml prevalence F2F3F4 9.7 % . Conclusion : The prevalence advance fibrosis estimate FibroTest , high ( 2.8 % ) HL follow tertiary center . This study strongly suggest non-invasive biomarkers could useful screen advanced fibrosis high-risk group hyperlipemic patient prevent liver mortality . Strategy management subject identify possible advanced fibrosis For subject possible advanced fibrosis , information give physician charge cohort . These subject could routine assessment advance liver fibrosis , include elastometry ( Fibroscan ) available reference centre ( Hepatology Department Groupe Hospitalier Pitié Salpêtrière ) independent sign cirrhosis ( ultrasonography endoscopy ) . Calendar This project conduct 3 year . Interdisciplinarity According wide population expose risk advance fibrosis , steatosis steatohepatitis , project possible several medical discipline involve . As described table 2 3 , project involve four different reference center : Viral Hepatitis Center ( Thierry Poynard ) , Diabetes Center ( Andre Grimaldi ) , Lipid Center ( Eric Bruckert ) , Alcoholic Center ( Sylvie Naveau ) , two Prevention Centers ( CPAM CDAG ) , one Anesthesiology department ( Pierre Coriat ) one Transfusion Unit ( Anne Mercadier ) . Originality Our group opportunity demonstrate feasibility screen first time world . We new non invasive biomarkers large number subject consult different participate center . The prevalence advance fibrosis asymptomatic cirrhosis , steatosis steatohepatitis establish France similar study could thereafter apply country .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Patients Exposed fibrosis risk factor ( HBV , HCV , ALD , NAFLD ) healthy volunteer Non reliable fibrosis estimate , follow short month , acute liver disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Fibrosis , HBV , HCV , ALD , NAFLD</keyword>
</DOC>